Anavex Life Sciences Corp. (AVXL)
3.105
-0.14
(-4.17%)
USD |
NASDAQ |
Aug 24, 16:00
3.10
0.00 (0.00%)
After-Hours: 20:00
Anavex Life Sciences Enterprise Value : 172.83M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 172.83M |
| August 20, 2026 | 162.64M |
| August 19, 2026 | 186.74M |
| August 18, 2026 | 169.13M |
| August 17, 2026 | 170.05M |
| August 14, 2026 | 170.98M |
| August 13, 2026 | 175.61M |
| August 12, 2026 | 188.59M |
| August 11, 2026 | 197.86M |
| August 10, 2026 | 186.74M |
| August 07, 2026 | 182.10M |
| August 06, 2026 | 176.54M |
| August 05, 2026 | 169.13M |
| August 04, 2026 | 164.49M |
| August 03, 2026 | 145.96M |
| July 31, 2026 | 127.43M |
| July 30, 2026 | 122.79M |
| July 29, 2026 | 103.33M |
| July 28, 2026 | 110.74M |
| July 27, 2026 | 104.26M |
| July 24, 2026 | 94.99M |
| July 23, 2026 | 102.40M |
| July 22, 2026 | 108.89M |
| July 21, 2026 | 109.35M |
| July 20, 2026 | 96.84M |
| Date | Value |
|---|---|
| July 17, 2026 | 94.06M |
| July 16, 2026 | 89.43M |
| July 15, 2026 | 104.26M |
| July 14, 2026 | 97.77M |
| July 13, 2026 | 90.36M |
| July 10, 2026 | 104.26M |
| July 09, 2026 | 122.79M |
| July 08, 2026 | 122.79M |
| July 07, 2026 | 123.72M |
| July 06, 2026 | 119.08M |
| July 02, 2026 | 128.35M |
| July 01, 2026 | 111.67M |
| June 30, 2026 | 112.60M |
| June 29, 2026 | 113.52M |
| June 26, 2026 | 115.38M |
| June 25, 2026 | 101.01M |
| June 24, 2026 | 109.82M |
| June 23, 2026 | 111.67M |
| June 22, 2026 | 107.96M |
| June 18, 2026 | 125.57M |
| June 17, 2026 | 120.01M |
| June 16, 2026 | 106.11M |
| June 15, 2026 | 104.26M |
| June 12, 2026 | 104.26M |
| June 11, 2026 | 104.26M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Tenaya Therapeutics, Inc. | 82.22M |
| Arrowhead Pharmaceuticals, Inc. | 12.07B |
| Oncolytics Biotech, Inc. | 101.41M |
| Sangamo Therapeutics, Inc. | 50.70M |
| Sarepta Therapeutics, Inc. | 2.242B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.338M |
| Total Expenses (Quarterly) | 5.338M |
| EPS Diluted (Quarterly) | -0.0576 |
| Earnings Yield | -12.59% |
| Normalized Earnings Yield | -12.59 |